In another blow, Argenx antibody therapy fails in trial for skin blistering condition; 3 trends to watch in biotech in 2024

Taking stock of the drug industry, from the lab to the medicine chest

December 20, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | In another blow, Argenx antibody therapy fails in trial for skin blistering condition Argenx said it was stopping the development of its antibody therapy in the autoimmune condition after the failed trial. By Andrew Joseph STAT+ | 3 trends to watch in biotech in 2024 Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, cutting-edge technologies, and some interesting mergers. By Damian Garde

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser